Pentoxifylline in treatment of sarcoidosis

American Journal of Respiratory and Critical Care Medicine

Volumn 155, Issue 5, 1997, Pages 1665-1669

  Zabel, Peter ^a   Entzian, Peter ^b   Dalhoff, Klaus ^b   Schlaak, Max ^b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; PENTOXIFYLLINE; PREDNISONE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG POTENTIATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; LUNG FUNCTION TEST; LUNG GRANULOMA; LUNG LAVAGE; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SARCOIDOSIS; THORAX RADIOGRAPHY;

EID: 0030926771     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.155.5.9154873     Document Type: Article

References (33)

1. Mitchell, D. N., and J. G. Scadding. 1974. Sarcoidosis. Am. Rev. Respir. Dis. 110:774-802.
2. Thomas, P. D., and G. W. Hunninghake. 1987. Current concepts of the pathogenesis of sarcoidosis. Am. Rev. Respir. Dis. 135:747-760.
3. Selroos, O., and T.-L. Sellergren. 1979. Corticosteroid therapy of pulmonary sarcoidosis. Scand. J. Respir. Dis. 60:215-221.
4. Hunninghake, G. W., S. Gilbert, R. Pueringer, C. Dayton, C. Floerchinger, R. Helmers, R. Merchant, J. Wilson, J. Galvin, and D. Schwartz. 1994. Outcome of the treatment for sarcoidosis. Am. J. Respir. Crit. Care Med. 149:893-398.
5. Kindler, V., A. P. Sappino, G. E. Grau, P. F. Piguet, and P. Vasalli. 1989. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740.
6. Müller-Quernheim, J., S. Pfeiffer, D. Männel, J. Strausz, and R. Ferlinz. 1992. Lung restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am. Rev. Respir. Dis. 145:187-192.
7. Zheng, L., H. Teschler, J. Guzman, K. Hubner, I. Striz, and U. Costabel. 1995. Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am. J. Respir. Crit. Care Med. 152:1061-1066.
8. Schade, F. U. 1990. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Cir. Shock 31:171-181.
9. Zabel, P., D. T. Wolter, M. M. Schönharting, and F. U. Schade. 1989. Oxpentifylline in endotoxaemia. Lancet 334:1474-1477.
10. Tannenbaum, C. S., and T. A. Hamilton. 1989. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J. Immunol. 142:1274-1280.
11. Funk, J. O., M. Ernst, M. M. Schönharting, and P. Zabel. 1995. Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int. J. Immunopharmacol. 17: 1007-1016.
12. American Thoracic Society. 1979. Snowbird Workshop on Standardization of Spirometry. Am. Rev. Respir. Dis. 119:831-838.
13. Quanjer, Ph. H., editor. 1983. Standardized lung function testing. Report of the Working Party "Standardization of Lung Function Tests," European Community for Steel and Coal. Bull. Eur. Physiopathol. Respir. 19:1-95.
14. Renzetti, A. D., Jr., E. R. Bleeker, G. R. Epler, R. N. Jones, R. E. Kanner, and L. H. Repsher. 1986. Evaluation of impairment/disability secondary to respiratory disorders. Am. Rev. Respir. Dis. 13:1205-1209.
15. York, E. L., T. Kovithavongs, S. F. P. Man, A. S. Rebuck, and B. J. Sproule. 1990. Cyclosporine and chronic sarcoidosis. Chest 98:1026-1029.
16. Demeter, S. L. 1988. Myocardial sarcoidosis unresponsive to steroids. Chest 94:202-203.
17. Lower, E. E., and R. P. Baughman. 1990. The use of low dose methotrexate in refractory sarcoidosis. Am. J. Med. Sci. 299:153-157.
18. Hof, D. G., P. C. Hof, and W. A. Godfrey. 1996. Long-term use of azathioprine as a steroid-sparing treatment for chronic sarcoidosis (abstract). Am. J. Respir. Crit. Care Med. 153:A870.
19. Müller-Quernheim, J., C. Saltini, P. Sondermeyer, and R. G. Crystal. 1986. Compartimentalized activation of the interleukin 2 gene by lung T lymphocytes in active pulmonary sarcoidosis. J. Immunol. 137:3475-3483.
20. Saltini, C., J. R. Spurzem, J. J. Lee, P. Pinkston, and R. G. Crystal. 1986. Spontaneous release of interleukin-2 by lung T Lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset. J. Clin. Invest. 77:1962-1970.
21. Strieter, R. M., D. G. Remick, P. A. Ward, R. N. Spengler, J. P. Lynch, III, J. Larrick, and S. L. Kunkel. 1988. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155:1230-1236.
22. Semmler, J., U. Gebert, J. Eisenhut. M. Möller, M. M. Schönharting, A. Alléra, and S. Endres. 1993. Xanthine derivates: comparison between suppression of tumor necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78:520-525.
23. Thanhäuser, A., N. Reling, A. Böhle, K. M. Toellner, M. Duchrow, D. Scheel, C. Schülter, M. Ernst, H. D. Flad, and A. J. Ulmer. 1993. Pentoxifylline: a potent inhibitor of IL-2 and gamma-IFN biosynthesis and BCG-induced cytotixicity. Immunology 80:151-156.
24. Rieneck, K., M. Diamant, P. J. Haahr, M. M. Schönharting, and K. Bendtzen. 1993. In vitro modulatory effects of pentoxifylline. Immunol. Lett. 37:131-137.
25. Rott, O., E. Cash, and B. Fleischer. 1993. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T-helper type 1-but not type 2-association lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1745-1751.
26. Rao, K. M. K., M. S. Currie, S. S. McCachren, and H. J. Cohen. 1991. Pentoxifylline and other methylxanthines inhibit interleukin-2 receptor expression in human lymphocytes. Cell Immunol. 135:314-325.
27. Zabel, P., and F. U. Schade. 1993. Pentoxifyline as an anti-tumor necrosis factor-alpha agent. Immun. Infect. Dis. 3:175-180.
28. Coccia, M. T., K. Waxman, M. H. Soliman, G. Tominaga, and L. Pinderski. 1989. Pentoxifylline improves survival following haemorrhagic shock. Crit. Care Med. 17:36-41.
29. Bianco, A. J., F. R. Appelbaum, J. Nemunaitis, J. Almgren, F. Andrews, P. Kettner, A. Shields, and J. W. Singer. 1991. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78:1205-1211.
30. Dezube, B. J., J. L. Fridovich-Keil, R. J. Allen, and A. B. Pardee. 1993. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol. Immunother. 36:57-60.
31. NIAID AIDS Clinical Trials Gorup. 1993. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J. Acquir. Immun. Defic. Syndr. 6:787-794.
32. Ward, A., and S. P. Clissold, 1987. Pentoxifylline. A review of its pharmacodynamic and pharmacocinetic properties, and its therapeutic efficacy. Drugs 34:50-97.
33. Neuner, P., G. Klosner, E. Schauer, M. Pourmojib, W. Macheiner, C. Grünwald, R. Knobler, A. Schwarz, T. A. Luger, and T. Schwarz. 1994. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83:262-267.